Semaglutide half-life: where the 165 to 184 hour figure comes from — what changed since

Post #13 describes the usual case. This is about the unusual one.

Offering a way to settle Semaglutide half-life rather than another opinion about it. Two measurements, taken the same way, a fortnight apart. If the difference is within the noise, the question was not answerable at this precision.

Adding the measurement that post #13 says would settle it.

Semaglutide versus liraglutide in STEP 8: semaglutide produced greater weight reduction and the discontinuation rates differed. But the trial was open-label for the dosing schedule, which admits expectation effects. Weekly versus daily itself is part of the comparison, not a confounding variable to be removed.

Research-use-only semaglutide is not a licensed medicine, is not manufactured to pharmaceutical standards, and is not approved for human use. That is a statement about what it is, not a coded opinion about anything.

Adding the caveat now so it does not have to be extracted later.

On identity confirmation: a mass close to 4113.6 Da on the intact molecule is consistent with semaglutide and is also consistent with several closely related species. Mass narrows the field; it does not close it, and no certificate should be read as though it did.

Happy to be the one who is wrong here if it settles the question.

Grateful for the specificity. Vague answers to this question are what sent me looking.

Post #17 answers the question as asked. The question underneath it is different.

I have three months of notes on Semaglutide half-life and the honest summary is that the trend is real and the week-to-week numbers are noise. I nearly drew the opposite conclusion from the first fortnight.

Is there a ceiling dose beyond which the effect plateaus? The trials did not study that because they stopped at 2.4 mg. Some people report trying higher doses, but trial data is absent and off-label dosing enters territory this site does not advise on.

Good question, well framed, and I would like to see it answered properly.

Building on post #21 rather than restating it.

Solutions of semaglutide can look faintly opalescent without anything being wrong. Visible particulate, fibres or frank cloudiness are a different observation entirely and are worth raising with the supplier rather than reasoning about.

The claim is narrower than it sounds, and deliberately so.

Adding what did not work for me on Semaglutide half-life, since the failures never get written up and they are half the useful information.

The C-cell question: semaglutide triggered medullary thyroid carcinoma in rodent toxicology studies. A signal in rodents does not automatically appear in humans, but it is the reason the compound is contraindicated in people with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2.

Discontinuation rates in the trials are worth reading alongside efficacy and almost never are. A large mean effect in a population where a meaningful fraction stopped early is telling you two things, not one.

Post #26 is the version of this I will quote in future. One addition.

An observation about Semaglutide half-life that I cannot explain and am posting anyway, on the principle that unexplained observations are more useful public than private.

Where I part company with post #24, and it is a narrow parting.

Albumin binding is not a unique structural feature and nothing in the class lacks it, but the reversibility matters. Semaglutide binds albumin covalently through a fatty side chain, which creates a very long half-life at the cost of sequestering the free form. That is a trade-off and it is the trade-off that allows weekly dosing.

I would call that likely rather than established.

The 165 to 184 hour half-life range gets quoted as a fixed number. It is a range across a studied population, and individual clearance varies enough that a person's own steady state may be reached earlier or later than the population average implies.

It cost nothing to check and would have cost something not to.

Where the Semaglutide half-life discussion usually stalls is that nobody wants to say "I do not know" and everyone is willing to say "it varies". Those are the same sentence with different clothes on.